



AERIS
BIOTECHNOLOGIES

A BREATH OF FRESH AIR IN ASTHMA CONTROL

Forward Looking Statements

This presentation contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Regulation A Disclaimer

This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply:

- No money or other consideration is being solicited, and if sent in response, will not be accepted;
- No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date;
- A person's indication of interest involves no obligation or commitment of any kind; and
- An offering statement has been filed with the Securities and Exchange Commission under Tier II of Regulation A. A copy of the preliminary offering circular that forms a part of the offering statement may be obtained at the following URL:


<https://www.sec.gov/Archives/edgar/data/1907923/000182912622008698/0001829126-22-008698-index.htm>

AERIS Investment Summary

- Groundbreaking unique approach to asthma and allergy control
- Natural, “green” technology that specifically targets a major source of asthma
- Technology protected by broad, **awarded** patents in key markets, including USA, UK, EU, Switzerland, Hong Kong, Japan, and Australia.
- Technology valuation predicted from published industry comparators in excess of \$200M after candidate product demonstrated
- Potential sales in patent protected markets alone exceed \$2B per annum
- Future markets will increase potential sales to upwards of \$4B

THE PROBLEM:

House Dust Mite Allergens



They're in your home. They're in your bed. And you can't get rid of them...


- At 0.3mm they're so small they are almost invisible
- A typical mattress holds more than 2,500,000 mites
- A female mite will lay 20-50 eggs in 3 months
- Mite droppings contain powerful allergens
- Each mite produces 20 droppings every day
- These allergens are a key cause of, and trigger for asthma attacks & other allergies

THE RESULT: Asthma

Imagine being paralyzed by fear as you struggle to breathe, unable to speak, unable to ask for help. That's what an asthma attack feels like.

Every two seconds someone is having a potentially life-threatening asthma attack somewhere in the United States. Every day, the lives of families across the USA are devastated by the death of a loved one to an asthma attack





Airways constricted during an asthma attack

- Asthma affects 339 million people worldwide
- It's a chronic, lifelong disease
- 400,000+ people die every year
- Costs exceed \$100 billion a year just in Europe and the US

House dust mites are a key cause of asthma and many other allergic diseases

CURRENT ASTHMA TREATMENTS:

Drugs

A wide range of drugs are used to treat asthma.

Expensive clinical trials are needed for new drugs

Despite this, asthma deaths are rising

So... why not prevent the effects of dust mite allergens by stopping them from ever reaching the patient in the first place?



The **AERIS** answer:

Stop the dust mites before the patient is exposed to their allergens

CURRENT DUST MITE TREATMENTS: Chemical and Physical Methods

A major scientific review bringing together over 50 different studies concluded that
"Chemical and physical methods aimed at reducing exposure to house dust mite allergens cannot be recommended"

Methods include chemicals, barriers, and filters

A family's costs can run into thousands of dollars per year

Billions of dollars are being spent

The need is so great...

Allergy 2008; 63: 646-659

© 2008 The Authors
Journal compilation © 2008 Blackwell Munksgaard
DOI: 10.1111/j.1398-9995.2008.01690.x

Review article

House dust mite control measures for asthma: systematic review

The major allergen in house dust comes from mites. We performed a systematic review of the randomized trials that had assessed the effects of reducing exposure to house dust mite antigens in the homes of people with mite-sensitive asthma, and had compared active interventions with placebo or no treatment. Fifty-four trials (3002 patients) were included. Thirty-six trials assessed physical methods (26 mattress covers), 10 chemical methods and eight a combination of chemical and physical methods. Despite the fact that many trials were of poor quality and would be expected to exaggerate the reported effect, we did not find an effect of the interventions. For the most frequently reported outcome, peak flow in the morning (1565 patients), the standardized mean difference was 0.00 (95% confidence interval (CI) -0.10 to 0.10). There were no statistically significant differences in number of patients improved (relative risk 1.01, 95% CI 0.80-1.27), asthma symptom scores (standardized mean difference -0.04, 95% CI -0.15 to 0.07) or in medication usage (standardized mean difference -0.06, 95% CI -0.18 to 0.07). Chemical and physical methods aimed at reducing exposure to house dust mite allergens cannot be recommended.

P. C. Gøtzsche, H. K. Johansen
Nordic Cochrane Centre, Rigshospitalet,
Copenhagen, Denmark

Key words: asthma; house dust mites; systematic review.

Dr Peter C Gøtzsche, MD, DrMedSci, MSc
The Nordic Cochrane Centre
Rigshospitalet, Department 3343
Blegdamsvej 9
DK-2100 Copenhagen Ø
Denmark

Accepted for publication 31 January 2008

And yet current approaches just don't work!




THE SOLUTION: *Aeris* Biotechnologies

Instead of treating the patient with drugs, or the environment with dangerous chemical pesticides,
Aeris treats the source

Aeris targets dust mites, specifically & exclusively, to stop them producing the allergens so that people are never exposed to their powerful and damaging effects

The *AERIS* approach is different:
Treat the SOURCE, not the Symptoms

The *AERIS* approach is different:
Treat the SOURCE, not the Symptoms



Aeris has a unique, patent protected approach that uses "green" biological control – natural agents that kill dust mites – a *biopesticide*

The US Environmental Protection Agency has stated "*biopesticides tend to pose fewer risks than conventional pesticides*"

The *Aeris* Approach: Biological Control



By preventing asthma before the patient is exposed, the risks of drugs and need for expensive clinical trials is avoided.

Biological control is able to spread out from initially treated areas to treat a whole room from a few, limited applications, and exerts control as long as its target is present

With a simple application to the carpets and injections into the furniture and bedding, dust mites can be naturally controlled

Infected dust mites become the vector that propagates the agent through the population

Aeris Product Strategy

Aeris' product will have unique advantages.

Projections assume:

Pricing estimated at a minimum of \$60 for a kit containing a unique, protected formulation

Kit is to be used 1-4 times a year, based on asthma/allergy severity

Uptake projections range from 1% among the worried well, to 25% for difficult-to-treat and severe asthmatics facing frequent hospitalization

Secondary markets add to this, including additional allergies, sales to hotels and businesses, and travel/car kits



AERIS Market Protection

Aeris controls **awarded** patents on its broad technology until 2036, including the USA, UK, Europe, Switzerland, Japan, Hong Kong, and Australia

Projections show a potential market in patent protected areas of more than \$2 billion for in-home use alone

Hospitality and commercial property/office sales will expand the market potential

Longer term, Aeris will target Indian and Chinese markets for further market expansion

AERIS has unique access to a multi-billion dollar potential market



European Patent Certificate

URKUNDE
Europäisches Patent
By word (deutsch) beschreibend, das für die in der Patentschrift beschriebene Erfindung ein europäisches Patent für die in der Patentschrift bezeichneten Vertragsstaaten erteilt worden ist.

CERTIFICATE
European patent
It is hereby certified that a European patent has been granted in respect of the invention described in the patent specification for the contracting States designated in the specification.


CERTIFICAT
Brevet européen
Il est certifié qu'un brevet européen a été décerné pour l'invention décrite dans le brevet, pour les Etats contractants désignés dans le brevet de brevet.

European Patent No. 3331366
Best available copy of the patent (Patent) is hereby issued.

Evolution Biotechnologies Ltd
Coburns Square Park
Bedford, Bedfordshire MK44 1LGGB

13.03.19

Andrea Campese
President of the European Patent Office
President of the European Patent Office



Hong Kong Patent Registry
The Government of the Hong Kong Special Administrative Region
知產處
Intellectual Property Department

In reply please quote this ref.: 1912005.2
Your ref.: EP19073 HK
Tel.: 2547 5278
Fax.: 2538 6315
09 April 2020

HONG KONG INTELLECTUAL PROPERTY CONSULTANCY LIMITED
ROOM 321, 1/F, WATSON COMMERCIAL BUILDING
28 CONNAUGHT ROAD WEST, SHEUNG WAN,
HONG KONG

Publication of request to record
In accordance with section 20(1)(b) of the Patents Ordinance, I would like to inform you that the request to record of the following standard patent application is published today:
Application no.: 1912005.2
Publication no.: 4000208

Upon any change of ownership of this application for patent, or change of name and/or address/addresses for service of the applicant, application should AT ONCE be made to the Registrar to register the change.

This is a letter issued by SOI Kin-lung for Registrar of Patents.
(This is a computer-generated copy. No signature is required.)

1912005.2(0001) Page 1 of 1

香港專利註冊處 註冊一(1)項發明專利：1項發明
Address: 2801-2802, New Wing Tower, 281 Connaught Road West, Hong Kong
電話: 2547 5278
傳真: 2538 6315

Consent to publish is required for the publication of the patent application. The applicant should submit a request to the Registrar of Patents to publish the patent application.



特許証
CERTIFICATE OF PATENT
特許第6840753号
PATENT NUMBER

発明の名称
(TITLE OF THE INVENTION) 抗ゲリ剤

特許権者
(PATENT PROPRIETOR) イギリス国、ヘッドフォードシャー県 エム・エー・4 イーエルキュー・ベッドフォード・シェンブルック・コルヴァース・サイエンス パーク 国路・地域 英国 (グレートブリテン及び北アイルランド連合王国) エボリューション バイオテクノロジーズ リミテッド

発明者
(INVENTOR) ハーパー、デイビッド アール。

公開番号
(PUBLICATION NUMBER) 特許2019-025822
公開日
(PUBLICATION DATE) 平成28年 8月 5日 August 4, 2016
登録日
(REGISTRATION DATE) 令和 3年 2月19日 February 19, 2021

この発明は、特許するものとして規定し、特許権者に与えられたことを証する。
(THIS IS TO CERTIFY THAT THE PATENT IS GRANTED TO THE APPLICANT OF THE JAPANESE PATENT OFFICE.)

特許庁長官
(COMPTROLLER, JAPANESE PATENT OFFICE) 増谷敏夫



Australian Government
IP Australia
23 April 2021

Notice of acceptance for patent application

FPA Patent Attorneys Pty Ltd
Level 42
101 Collins Street
Melbourne VIC 3000
Australia

Your reference M20190306
Application number 2016305553
Applicant name Evolution Biotechnologies Ltd

Dear FPA Patent Attorneys Pty Ltd,
This patent application was accepted on 12 April 2021. The accepted specification incorporates the following amendments:
PCT: WO2017023702
S104 amendments up to and including item number: 4
The total number of claims at acceptance has been reported as: 19
Notice of the acceptance will appear in the Australian Official Journal of Patents on 6 May 2021.
Please review the acceptance details attached to this letter to ensure that they are correct. If you wish to amend any details prior to the grant please do so within 3 months of the advertisement of acceptance.
An invitation to pay (IPFPA) the acceptance fee will be issued to you. This fee will include an additional component if the number of claims exceeds 20.
Details of this patent application can be viewed on ipau.gov.au, our Australian patent search database.

Yours sincerely,
IP Australia

This data, for application number 2016305553, is current as of 2021-05-15 21:00 AEST Page 1 of 3

The *AERIS* Team

Dr. David R. Harper, Chairman, CSD

- 20+ years' biotechnology experience
- Brought first company to an NYSE listing
- Expert microbiologist with books, papers, and multiple patents
- Pioneering worker on biological control of the house dust mite

Aaron M. Gunn, CEO

- 20+ years' experience founding and growing companies
- Active investor in multiple private companies in technology and banking Extensive experience in managing business operations

Edward C. Cappabianca, CBO

- 20+ years' experience advising and raising capital
- Highly experienced investment banker, guiding progress to public listing
- Broad experience as biotechnology C-grade officer

Steven Portnoy, Corporate Legal Counsel

- Experienced corporate lawyer, more than 35 years in US practice
- 25+ years' experience in founding/operating successful companies



Aeris Investment Summary

- Technology is protected by broad, **awarded** patents in key markets
- Sales potential in excess of \$2 billion annually
- Technology valuation at completion of trials is expected to be in the hundreds of millions of dollars on way to a multi-billion dollar market
- Data showing effect then to support progress to market through joint ventures
- Public market listing planned upon achievement of near term milestones



AERIS
BIOTECHNOLOGIES

Treating the **SOURCE**, not the **SYMPTOMS**

aerisbiotech.com